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Abstract
Background: Ovarian cancer is the leading cause of death from gynaecological cancer 
worldwide.
Objectives: This study was to determine the prevalence, risk factors, clinical presentations, 
treatment modalities and outcome of ovarian cancer in a tertiary health care institution. 
Materials and Methods: A 5-year retrospective study of patients with ovarian cancer managed 
in Nnamdi Azikiwe University Teaching Hospital (NAUTH), Nnewi, South Eastern Nigeria, 
st
between 1  January 2003 and 31st December 2007 was undertaken. The data was collected by 
scrutinizing the case files collected from the medical records department,
Results: There were 29 cases of ovarian cancer out of total of 122(23.8% of all gynaecological 
malignancies) gynaecological malignancies and2.9% of 1003 gynaecological admissions. The 
mean age of the patients was 52.9 + 1.7 years. More than 60% of the patients were above 50 
years and 66.7% were grandmultipara. Abdominal swelling (47.8%) followed by abdominal pain 
(13.7) were the commonest presenting symptoms. Only 2 (7.4%) patients had a family history of 
cancer. Stage III (76.9%) was the modal stage at presentation. Approximately 63% were 
epithelial tumours. Most of the patients (88.9%) had cytoreductive surgery and 92.3% of these 
had adjuvant chemotherapy. Two (7.6%) patients died intra-operatively, while 75.0% of the 
patients died within 6 months of therapy.
Conclusion: The prevalence of ovarian cancer was high in Nnewi and environs. Majority of 
patients presented late and mortality was high despite multimodal therapy. Public 
enlightenment to increase awareness and introduction of screening programme for early 
detection is advocated. 
1developing the condition . clinical presentations, histo-pathological 
types, treatment modalities and the 
In high risk populations especially in BRCA1 outcome of management of ovarian cancer 
and BRCA2 mutation carriers, strategies to in Nnamdi Azikiwe University Teaching 
either prevent ovarian cancer or make Hospital (NAUTH), Nnewi South-East 
8 Nigeria. The information obtained from this earlier diagnosis are of importance . 
review will undoubtedly help in suggesting Whereas women from the general 
strategies for detection and improvement in population have a 1-2% lifetime risk of 
the level of care given to these patients.developing ovarian cancer, those with  germ 
line  mutation in the BRCA and tumour 
Materials and Methodssuppressor genes have an approximately 
8 We undertook a retrospective study of all the 40% lifetime risk of  developing  the disease . 
patients with ovarian cancer who were The increased awareness of the genetic risk 
admitted into the gynaecological ward of the factors associated with ovarian cancer and 
Nnamdi Azikiwe University Teaching the mortality associated with the condition 
Hospital (NAUTH), Nnewi, South East, has lead to demands for ovarian cancer 
Nigeria, between 1st January 2003 and 31st screening by both the public and health 
1 December 2007 (A 5 - year period).professionals . 
The names and hospital numbers of all Despite advances in the diagnosis and 
patients with ovarian cancer managed were treatment, mortality rates have not 
9 extracted from the gynaecological ward improved significantly in recent years . The 
register. The gynaecological ward register poor prognosis is related to the advanced 
also provided the total number of stage at presentation and strategies to 
g y n a e c o l o g i c a l  a d m i s s i o n s  a n d  diagnose ovarian cancer at an earlier stage 
1 gynaecological malignancies over the study are therefore warranted . Furthermore, 
period.more women die from ovarian cancer than 
from the carcinoma of the cervix and 
8 We recorded 29 cases of ovarian cancer out carcinoma of body of the uterus combined .
of 122 gynaecological malignancies and 
1003 gynaecological admissions. Only 27 Against this backdrop, this study aims to 
case files (93.1%) were retrieved from the determine the prevalence, risk factors, 
2,5Introduction incompletely understood,   however, it is 
Ovarian cancer is the leading cause of death believed  that repeated ovulation may be  
1,2 5,6among gynaecological cancers . Although it the stimulus for tumour initiation . This is 
accounts for only 3-4% of cancer in women, borne out by the observation that factors 
it is the fourth leading cause of cancerrelated associated with reduced number of 
death in females in the United Kingdom and ovulations are protective for cancer of the 
2,3,4 . 5United State  It is the third commonest ovary . These factors include prolonged use 
cause of cancer related death in African of the oral contraceptives, multiparity, 
5
women . The high mortality associated with prolonged breastfeeding and chronic 
5,7ovarian cancer is mainly due to late anovulation.  A positive family history of 
presentation at which most cases are ovarian cancer is a strong risk factor for 
2diagnosed . Generally, cancer of the ovary is 
a disease of the postmenopausal women 
with the highest incidence in patients aged 
2,3
65-70years.  
The aetiology of ovarian cancer is 
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Table 1: The Age Distribution of the Patients with Ca Ovary Seen  in NAUTH, Nnewi.
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medical records department of the hospital. 
The mean age of the patients was 52.9 + 1.7 Information on the age, parity, risk factors, 
years, with a range of 13-81 years. The age clinical presentations, histo-pathological 
distribution of the patients is shown in types, treatment options and outcomes  
table1.were extracted from the case files. The data 
The highest prevalence  were found in two was entered into a computer and analysed 
age groups- 51-60 years and  71-80 years, using the EPI-INFO version 3.3.2 software. 
each  accounting  for 33.3% and 22.3% of the Results are presented as percentages and 
patients respectively. Only 2 (7.4%) of the tables.
patients were 30 years or younger while 17 
(63.0%) of the patients were above 50years Results
of age. The parity of the patients ranged from During the five-year study period, there 
0 to 10. The majority, 18 (66.7%)  patients were a total of 29 cases of ovarian cancer 
were grand-multiparous, 9 (29.6%) were admitted out of the 1003 gynaecological 
multiparous, while only 1 (3.7%) was admissions giving a prevalence of 2.9%. Also, 
nulliparous. This is shown in table 2. Of the in this period of study, there were 122 cases 
possible risk factors recorded in the patients' of gynaecological malignancies and hence 
case files two (7.4%) patients had family ovarian cancer constituted 23.8% of all 
history of cancer, 1 (3.7%) had used oral gynaecological malignancies.
contraceptive pills, while none had any chemotherapy.
history of the use of ovulation induction 
drugs. Table 4: Shows the histological types of 
Table 3 shows the clinical symptoms / ovarian cancer seen in the patients. It was 
features of the patients. The majority 21 predominantly of the epithelial type.  The 
(47.8%) of the patients presented with commonest histological type was serous 
abdominal swelling, followed by abdominal cyst-adenocarcinoma (33.3%) followed by 
pain, 6(13.7%) and weight loss, 3 (9.1%) mucinous cyst-adenocarcinoma (25.0%), 
endodermal sinus (yolk sac) (16.7%) and 
Almost all the patients, 26 (96.3%) had granulosal cell tumour (12.5%).
exploratory laparatomy while only 1(3.7%) 
had no surgery. The commonest surgical The stage of the disease at laparatomy is 
procedure performed at laparatomy was shown in table 5. Stage III was the most 
primary debulking (cyto-reduction) 88.9% common diagnosis (76.9%) followed by stage 
followed by total abdominal hysterectomy IV (15.4%) and stage II. No patient had stage I 
(TAH) and bilateral salpingo-ophorectomy disease.
(BSO) 7.4%. None of the patients had BSO 
alone. Of the 26 patients that had surgery 24 Table 6 shows the outcome of the follow up 
(92.3%) received adjuvant chemotherapy of the patients that received chemotherapy. 
while 2 (7.6%) did not. One of the patients Of  the 25 pat ients  that  received 
died intra-operatively due to haemorrhage chemotherapy, majority, 13 (52.0%) were 
and the other was due to anaesthetic death. lost to follow up, while only 4 (16.0%) 
Only 1 (3.7%) patient received neo-adjuvant received six courses of chemotherapy 
Table 2: The Parity Distribution of the Patients with Ovarian Cancer Seen in NAUTH Nnewi.
Parity                         Frequency Percentage (%)
0 1 3.7
1-4 8 29.6
> 5 18 66.7
Total 27 100
* Many patients presented with more than one symptom.
Table 3: The Presenting Symptoms of Patients with Ovarian Cancer Seen  in NAUTH, Nnewi.
Symptom             Frequency Percentage (%)
Abdominal swelling 21 47.8
Abdominal pain 6 13.7
Weight loss 4 9.1
Vaginal bleeding 3 6.8





Table 4: The Histological Type of Ovarian Cancer Seen in NAUTH Nnewi.
Histological Type                         Frequency Percentage (%)
Serous cyst-adenocarcinoma 8 33.3
Mucinous cyst-adenocarcinoma 6 25.0
Endodermal sinus tumour 4 16.7
Granulosal cell tumour 3 12.5
Borderline 2 8.3
Clear cell tumour 1 4.2
Total 24 100
Table 5: The Staging Laparatomy Findings of Patients with Cancer Seen in NAUTH Nnewi.
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( C i s p l a t i n ,  A d r i a m y c i n  a n d  patients with ovarian cancer were 50years or 
cyclophosphamide). Of the 12 patients who younger. It also compared favourably with 
were not lost to follow up, 9 (75.0%) died peak age incidence of 65-74 years reported 
2,3within 6months of commencing therapy. in developed countries . The probable 
reason  for this high  peak  age of  incidence 
Discussion could be  that  cancer  of the ovary  is a  
In this study, the prevalence of ovarian disease of the post menopausal women and 
cancer was 2.9%. This finding was quite high in Nigeria, the mean age of menopause is 
11 3 , 1 5when compared to 1.5% in Ibadan . Also this 48years plus or minus 5 years .  
study has revealed that ovarian cancer Furthermore, the fact that there was no 
constituted 23.8% of all gynaecological reliable screening test for cancer of the ovary 
1,16malignancies in our centre. This figure was may be contributory for this findings . As a 
higher than few reports from other parts of result most patients present only when 
11Nigeria, such as 9.8% in Ibadan , 11.9% in condition has become full blown and 
12 13
Benin  and 16.3% in Maiduguri  but lower advanced. In this regard, younger women 
14 might have been treated by herbalists or not than 27.0% in Kano . It was also higher than 
present at all for treatment.the overall worldwide rate of 3-4% of all 
gynaecological malignancies.
Multiparity is said to be protective for 
5The increased  prevalence rate in our  centre ovarian cancer , rather this was not the case 
may be due to the status of the hospital as a  in our findings in the study. The majority of 
referral centre  from  various clinics both patients (66.7%) in our study were grand-
private and  public; it is also  probably due to multiparous. This however was not in 
11,12the reduced number of  the total  agreement with other studies  and in the 
2,3,17gynaecological admissions over the years of literature . Pregnancy was expected to be 
study when  compared to other centres like associated with a risk reduction of 13-19% 
3Ibadan which has  high  volume of  total per pregancy . The reason why high parity 
gynaecological admissions. In addition, predominates in the patients with ovarian 
Westernized life style among our women folk cancer could be that high parity was not an 
could be responsible. independent protective factor in ovarian 
cancer development. This calls for further 
In this study, the peak age of prevalence of investigation.
ovarian cancer was 51-60years. The mean 
age was 52.9 + 1.7years. This finding was in Abdominal swelling, abdominal pain and 
line with the report in Benin where the peak weight loss were the most frequently 
age of incidence was also between 51- reported symptoms in this study, this agrees 
12 11 1260years , but differ greatly from the study in fully with the study in Ibadan , Benin  and 
11 2,3,17Ibadan  where more than 60% of the documentations in the  literature . The 
abdominal swelling may be due to the was classed as ASA class 4 following 
enlarging ovarian mass or ascites. Weight anaesthetic review. The neo adjuvant 
loss may have occurred in association with chemotherapy would have made the 
1 7 2
chronic anorexia  often leading to delayed primary operation much easier .
malnutrition. These symptoms would have 
been different if the patients presented The commonest histological type of ovarian 
earlier. cancer in this study was serous cyst-
adenocarcinoma, accounting for 33.3% 
The majority of our patients (76.9%) followed by mucinous cyst-adenocarcinoma 
presented with stage III disease followed by (25.0%). This agrees with the studies in 
11,12,14stage IV (15.4%). Up to 76.2% of patients had various regions in Nigeria  and with the 
stage III disease in a similar study conducted literature where the majority of ovarian 
11 12 2,3,17in Ibadan  and Benin . The stage of tumours were of epithelial origin . Like in 
presentation affects the prognosis and from our study,  granulosa cel l  tumour,  
this it showed that they all had poor endodermal sinus tumour and clear cell 
prognosis. This advanced stage of the tumour were also reported in a study in 
14disease at presentation is a direct result of Kano, Nigeria .
late presentation as already outlined. The 
reason for late presentation could be that In this study, more than 50% of the patients 
early symptoms of ovarian cancer are non that had surgery were lost to follow up. The 
s p e c i f i c  a n d  s o  t h e r e  w e r e  n o  reason for this could not be explained. It 
2,3,17
pathognomonic clinical features . could be probably that some of them died at 
home from the effect of the disease because 
In this review, cyto-reductive surgery or most presented with advanced disease or 
debulking was the commonest surgical from the side effect of the chemotherapy. It 
procedure performed at laparatomy. The could also be that they could not continue 
reason for this finding could be that majority spending money on chemotherapy since 
of the patients presented late. The aim of the most people believe that diagnosis of cancer 
2surgery as explained by Gabra  is to was synonymous to death sentence. This 
macroscopically debulk the tumour to make could also explain why 32.0% of the patient 
chemotherapy more effective. This was true received less than 6 courses of the 
12 chemotherapy.of the report in Benin  where the majority of 
the patients had cyto-reductive surgery as 
The case fatality of the patients that were not the first line of treatment while more than 
lost to follow up was 75%. This figure was 85% of patients had adjuvant chemotherapy. 
quite high. The patients presented late and In our study, more than 90% of patients that 
2h a d  s u r g e r y  r e c e i v e d  a d j u v a n t  treatment could be efficatious at this stage . 
chemotherapy comprising of Cisplatin, This further buttresses the fact that more 
adriamycin and cyclophosphamide.   This women die from ovarian cancer than from 
was given on a 3 weekly courses and a the carcinoma of the cervix and the body of 
10minimum of 6 courses. In our centre, the uterus combined . This finding agrees 
18adjuvant chemotherapy applied to all with findings at Ibadan and Enugu, Nigeria .
patients.
In conclusion, the prevalence of ovarian 
In this study, only one (3.7%) patient cancer was high in Nnewi and environs. The 
received neo-adjuvant chemotherapy. This majority of the patients presented late and 
patient was not operated upon because she the mortality was high despite multimodal 
Table 6: The Outcome at Follow-Up of Patient on Chemotherapy at NAUTH Nnewi.
Course                  Frequency Percentage (%)
6 Courses 4 16.0
< 6 Courses 8 32.0
Lost of Follow up 13 52.0
Total 25 100
104103
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therapy. This calls for screening programmes with cancers in our environment to ensure 
a n d  a w a r e n e s s  c a m p a i g n  i n  o u r  that treatments are available at minimal 
communities. Is parity associated with rate. The social health workers should be 
ovarian cancer? A study is needed in this encouraged to institute an effective follow 
area. More importantly, there is need for up of cancer patients since many of them do 
improved social welfare package for patients not come back to hospital after diagnosis.
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